Linked Life Data

8693654

Source:http://linkedlifedata.com/resource/pubmed/id/8693654

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1996-8-26
pubmed:abstractText
Although prostate-specific antigen (PSA) screening has not been demonstrated to reduce prostate cancer mortality in the clinical trial or population setting, the use of PSA for screening increased during the early 1990's. A clinical trial is currently underway to test the efficacy of PSA screening; however, the results will not be available for at least 10 years. To address concerns about the effectiveness of PSA screening in the near term, population-based assessments of PSA screenings are needed. To reduce mortality, PSA screening must first produce improved survival. In New Mexico, increased screening was associated with a stage migration from distant to earlier stages and an increase in 5-year relative survival, suggesting that PSA screening may be effective.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0090-4295
pubmed:author
pubmed:issnType
Print
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
67-71
pubmed:dateRevised
2010-3-24
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen ERA.
pubmed:affiliation
Department of Medicine, University of New Mexico School of Medicine, Albuquerque, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.